People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OncoVerity, Inc. | — | Biotechnology | Series A | $18.0M | $60.5M | 2024 |
| P2 Science, Inc. | — | Biotechnology | Series B | $15.8M | $619.5M | 2011 |
Kimberly Muller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kimberly Muller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert A Bettigole | 1 | 3 |
| Steven Hess | 1 | 2 |
| Kip A. Frey | 1 | 2 |
| Robert Bettigole | 1 | 2 |
| Petra Van Vlierberghe | 1 | 1 |
| Clayton Smith | 1 | 1 |
| Steven VanNurden | 1 | 1 |
| Kevin A. Gallagher | 1 | 1 |
| Hapiz A. Abdullah | 1 | 1 |
| Neil A. Burns | 1 | 1 |
| Neil Burns | 1 | 1 |
| Massimiliano Colao | 1 | 1 |
| Arjen Lemmen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.